These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 24750217)
1. Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis. Miller MH; Walsh SV; Atrih A; Huang JT; Ferguson MA; Dillon JF J Gastroenterol Hepatol; 2014 Oct; 29(10):1839-47. PubMed ID: 24750217 [TBL] [Abstract][Full Text] [Related]
2. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Kamada Y; Ono M; Hyogo H; Fujii H; Sumida Y; Mori K; Tanaka S; Yamada M; Akita M; Mizutani K; Fujii H; Yamamoto A; Takamatsu S; Yoshida Y; Itoh Y; Kawada N; Chayama K; Saibara T; Takehara T; Miyoshi E Hepatology; 2015 Nov; 62(5):1433-43. PubMed ID: 26199205 [TBL] [Abstract][Full Text] [Related]
3. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Colak Y; Senates E; Ozturk O; Yilmaz Y; Zemheri E; Yilmaz Enc F; Ulasoglu C; Aksaray S; Bozbeyoglu SG; Kiziltas S; Kurdas OO; Tuncer I Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):255-61. PubMed ID: 22157234 [TBL] [Abstract][Full Text] [Related]
4. High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease. Maleki I; Rastgar A; Hosseini V; Taghvaei T; Rafiei A; Barzin M; Torabizadeh Z; Naghshvar F; Khalilian A Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1583-90. PubMed ID: 24943967 [TBL] [Abstract][Full Text] [Related]
5. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease. Yilmaz Y; Eren F Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1292-5. PubMed ID: 25171027 [TBL] [Abstract][Full Text] [Related]
6. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease. Amacher DE Biomarkers; 2014 Nov; 19(7):541-52. PubMed ID: 25189636 [TBL] [Abstract][Full Text] [Related]
7. Serum retinol binding protein 4 and galectin-3 binding protein as novel markers for postmenopausal nonalcoholic fatty liver disease. Cai H; Lu S; Chen Y; Das Mbbs Mrcog S; Niu Z; Zhuo G; Lai L; Zhang Z Clin Biochem; 2018 Jun; 56():95-101. PubMed ID: 29679552 [TBL] [Abstract][Full Text] [Related]
8. Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. Hou W; Janech MG; Sobolesky PM; Bland AM; Samsuddin S; Alazawi W; Syn WK Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31860081 [TBL] [Abstract][Full Text] [Related]
9. Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. Yilmaz Y Clin Chim Acta; 2012 Aug; 413(15-16):1190-3. PubMed ID: 22546610 [TBL] [Abstract][Full Text] [Related]
10. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. Yu C; Xu C; Xu L; Yu J; Miao M; Li Y J Hepatol; 2012 Jan; 56(1):241-7. PubMed ID: 21756851 [TBL] [Abstract][Full Text] [Related]
11. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333 [TBL] [Abstract][Full Text] [Related]
12. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Nobili V; Alkhouri N; Alisi A; Ottino S; Lopez R; Manco M; Feldstein AE Clin Gastroenterol Hepatol; 2009 May; 7(5):575-9. PubMed ID: 19268270 [TBL] [Abstract][Full Text] [Related]
14. [Research advances in diagnosis of non-alcoholic fatty liver disease]. Wang JH; Yu CH Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):115-118. PubMed ID: 28297797 [TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. Zhang JZ; Cai JJ; Yu Y; She ZG; Li H Gene Expr; 2019 Nov; 19(3):187-198. PubMed ID: 31010457 [TBL] [Abstract][Full Text] [Related]
16. Current status of fibrosis markers. Patel K; Shackel NA Curr Opin Gastroenterol; 2014 May; 30(3):253-9. PubMed ID: 24671009 [TBL] [Abstract][Full Text] [Related]
17. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Bell LN; Theodorakis JL; Vuppalanchi R; Saxena R; Bemis KG; Wang M; Chalasani N Hepatology; 2010 Jan; 51(1):111-20. PubMed ID: 19885878 [TBL] [Abstract][Full Text] [Related]
18. Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease. Sanchez-Pareja A; Clément S; Peyrou M; Spahr L; Negro F; Rubbia-Brandt L; Foti M World J Gastroenterol; 2016 Apr; 22(14):3735-45. PubMed ID: 27076758 [TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. Cianfarani S; Inzaghi E; Alisi A; Germani D; Puglianiello A; Nobili V J Pediatr; 2014 Jul; 165(1):92-8. PubMed ID: 24607243 [TBL] [Abstract][Full Text] [Related]
20. Proteomics analysis of human nonalcoholic fatty liver. Rodriguez-Suarez E; Mato JM; Elortza F Methods Mol Biol; 2012; 909():241-58. PubMed ID: 22903720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]